- Home
- ODYS vs VERU Comparison
ODYS vs VERU Comparison
Compare ODYS & VERU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ODYS
- VERU
- Stock Information
- Founded
- ODYS N/A
- VERU 1971
- Country
- ODYS Israel
- VERU United States
- Employees
- ODYS N/A
- VERU N/A
- Industry
- ODYS
- VERU Biotechnology: Pharmaceutical Preparations
- Sector
- ODYS
- VERU Health Care
- Exchange
- ODYS NYSE
- VERU Nasdaq
- Market Cap
- ODYS 86.1M
- VERU 76.9M
- IPO Year
- ODYS N/A
- VERU 1990
- Fundamental
- Price
- ODYS $5.36
- VERU $0.52
- Analyst Decision
- ODYS Strong Buy
- VERU Strong Buy
- Analyst Count
- ODYS 1
- VERU 3
- Target Price
- ODYS $10.00
- VERU $4.33
- AVG Volume (30 Days)
- ODYS 32.2K
- VERU 805.1K
- Earning Date
- ODYS 03-28-2025
- VERU 05-08-2025
- Dividend Yield
- ODYS N/A
- VERU N/A
- EPS Growth
- ODYS N/A
- VERU N/A
- EPS
- ODYS N/A
- VERU N/A
- Revenue
- ODYS $3,964,000.00
- VERU $16,886,419.00
- Revenue This Year
- ODYS N/A
- VERU N/A
- Revenue Next Year
- ODYS N/A
- VERU N/A
- P/E Ratio
- ODYS N/A
- VERU N/A
- Revenue Growth
- ODYS 30.70
- VERU 134.43
- 52 Week Low
- ODYS $5.01
- VERU $0.45
- 52 Week High
- ODYS $10.80
- VERU $1.64
- Technical
- Relative Strength Index (RSI)
- ODYS N/A
- VERU 47.44
- Support Level
- ODYS N/A
- VERU $0.48
- Resistance Level
- ODYS N/A
- VERU $0.56
- Average True Range (ATR)
- ODYS 0.00
- VERU 0.03
- MACD
- ODYS 0.00
- VERU -0.00
- Stochastic Oscillator
- ODYS 0.00
- VERU 44.50
About ODYS ODYSIGHT AI INC
Odysight ai Inc is engaged in the development, production, and marketing of Predictive Maintenance (PdM) and Condition Based Monitoring (CBM) technologies, providing visual sensing and AI-based video analytics solutions for critical systems in the aviation, maritime, industrial non-destructing-testing industries, transportation, and energy industries.
About VERU Veru Inc.
Veru Inc is a biopharmaceutical company with a drug development program for the treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). The company is also in the late-stage development of certain drugs for the management of breast and prostate cancers. It also has a sexual health program that includes two products, ENTADFI, for the treatment of benign prostatic hyperplasia (BPH) and the FC2 Female Condom (Internal Condom). The company operates in a single segment and generates revenue from the USA which is the key revenue generating market, Brazil, and other regions.